Ibrutinib as a single agent or in combination with rituximab or obinutuzumab or venetoclax
is indicated for the treatment of adult patients with previously untreated chronic lymphocyticleukaemia (CLL)
Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) isindicated for the treatment of adult patients with CLL who have received at least one priortherapy.
Ibrutinib as a single agent is indicated for the treatment of adult patients with Waldenström"smacroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatmentfor patients unsuitable for chemoimmunotherapy.
Ibrutinib in combination with rituximab is indicated for the treatment of adult patients withWM.
The treatment of the following infections:
1. As part of a multidrug regimen in the treatment of all forms of leprosy.
2. Treatment of blistering dermatoses such as dermatitis herpetiformis.
3. Prophylaxis of Pneumocystis jirovecii pneumonia in immunodeficient subjects, especially AIDS patients.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Adults
Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight.
Paediatric population
Treatment of juvenile idiopathic arthritis (in combination with other therapies), discoid and systemic lupus erythematosus.
Deferasirox is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.
Deferasirox is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
- in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,
- in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older,
- in adult and paediatric patients with other anaemias aged 2 years and older.
Deferasirox is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with nontransfusion-dependent thalassaemia syndromes aged 10 years and older.
Deferasirox is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.
Deferasirox is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
- in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,
- in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older,
- in adult and paediatric patients with other anaemias aged 2 years and older.
Deferasirox is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with nontransfusion-dependent thalassaemia syndromes aged 10 years and older.
This medicinal product is for diagnostic use.
Ultravist-240, -300, -370:
–Angiography, angiocardiography, digital subtraction angiography
–Contrast enhancement in computerised tomography
–Urography
–Visualization of body cavities
(Exception: myelography, ventriculography, cisternography)
Ultravist-300/-370:
Used in adult women for contrast-enhanced mammography to assess and detect known or suspicious lesions of the breast,
–in addition to mammography (with or without ultrasound) or
–as an alternative to magnetic resonance imaging (MRI) if MRI is contraindicated or not available.
